United States Patent 8,431,576 scope and claims: what the compound Markush claims actually cover
US 8,431,576 is a Markush-claim US compound patent with broad structural coverage and heavy latitude for substituents and salts/solvates. Claims 1–7 define a general chemical core “Formula” and then expand coverage across: (i) geometric isomers, enantiomers, diastereomers, and racemates; (ii) pharmaceutically acceptable salts; (iii) solvates; and (iv) wide combinatorial substitution using parameter sets R2, R3, R4, R5, R6, R10, R11, R20/R21, and integer ring/chain variables (p, r, z, t, s, m, q, u, w, etc.).
Claims 4–7 narrow to Table-driven selections of R5 and “selected compound” lists (Tables A–E), indicating the specification contains enumerated embodiments that map to concrete structures.
Bottom line for freedom-to-operate (FTO) and generic entry risk: the claims are written to capture large families of analogs around a shared scaffold, and the later dependent claims that point to Tables suggest the patentee’s allowed embodiments are a subset of the Markush universe, not a full surrender of breadth.
What is the scope of claim 1 in US 8,431,576 (core structure, substituent variables, and salts/solvates)?
Claim 1 is the foundational Markush compound claim. It covers “a compound having the Formula” (substituted scaffold), including:
1) Isomeric and physical-form scope
Claim 1 expressly includes:
- geometric isomers
- enantiomers
- diastereomers
- racemates
- pharmaceutically acceptable salts
- solvates
This is important because it converts the patent from a single-molecule fence into a broader material fence that captures alternate stereoisomeric and form variants.
2) Substitution scope for R2, R3, R4 (core side heteroatoms and aromatic/aliphatic latitude)
Claim 1 defines each of R2, R3, and R4 using the same option set:
Each of R2/R3/R4 is selected from:
- absent
- hydrogen
- halogen
- —OR10
- —SR10
- —N(R10)(R11)
- —S(O)R10
- —S(O)2R10
- optionally substituted aliphatic
- optionally substituted aryl
- optionally substituted heterocyclyl
Key takeaways for scope:
- Oxygen/sulfur hetero-substitutions (OR10, SR10, sulfoxide, sulfone) are explicitly enabled.
- The claim is not limited to a single ring system for R2/R3/R4; heteroaryl and aliphatic substituents are permitted.
- “Optionally substituted” means additional substituents are allowed on those substituent groups, which expands the match space for non-identical analogs.
3) R5 is the largest driver of combinatorial coverage
Claim 1 defines R5 via a set of backbone-link patterns that include:
- ether/carbonyl ether motifs: —CH(R10)—OR20; —CH(R10)—OC(O)OR20; —CH(R10)—OC(O)R20
- amino carbonyl ester motif: —CH(R10)—OC(O)NR20R21
- phosphate/ phosphonate motifs:
- —(CH(R10))—OPO3MY
- —(CH(R10))—OP(O)(OR20)(OR21)
- cyclic/oligomeric linker patterns:
- —[CH(R10)O]z—R20
- —[CH(R10)O]z—C(O)OR20
- —[CH(R10)O]z—C(O)R20
- —[CH(R10)O]z—C(O)NR20R21
- —[CH(R10)O]z—OPO3MY
- —[CH(R10)O]z—P(O)2(OR20)M
- —[CH(R10)O]z—P(O)(OR20)(OR21)
With:
- z = 1 to 7 (a defined oligomer length range)
- R20 and R21 independently = hydrogen, aliphatic, substituted aliphatic, aryl, substituted aryl
- Y and M are monovalent cations; or M and Y together form a divalent cation
Scope implication: R5 allows multiple functional “solubilizing or prodrug-like” groups: esters, carbamates/amides, and phosphate salt/phosphoryl patterns. This is typical of patents covering prodrug derivatives and salt forms designed for absorption.
4) R10 and R11 (substituent attachment variability)
Claim 1 defines:
- R10 = absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl, substituted aryl
- R11 = absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl, substituted aryl
This means the claim allows either “blank” (absent) or hydrogen or halogen or diverse aryl/aliphatic substituents on substituent positions.
5) Core ring/connector variables (D, m/q, p, r, and t/s)
Claim 1 includes additional structural variables:
- D is selected from:
- absent
- —O—
- —NR10
- —C(R10)(R11)—
- and sulfur analogs: —S—, —S(O)—, —S(O)2—
- carbonyl: —C(O)—
- m and q independently = 0, 1, or 2
- p = 0–4
- r = 0–11
- t and s independently = 0, 1, or 2
These parameters allow multiple expansion patterns for heteroatom placement and ring fusion/degree, increasing the range of scaffold instantiations while still tying them to the same generic “Formula.”
6) R6 variable groups and “two adjacent R6 groups form a second ring”
Claim 1 defines R6 as independently selected from:
- hydrogen, halogen, OR10, SR10, NR10R11
- aliphatic, substituted aliphatic
- aromatic, substituted aromatic
and allows that two adjacent R6 groups form a second ring.
This is a structural breadth amplifier. It means the patentee is not restricted to simple substituent patterns on a fixed core; a subset of substitution patterns can cyclize into an additional ring system and still fall within the claim.
How does claim 2 narrow or modify the Markush set for R5 (w variable)?
Claim 2 is a dependent claim that recites a compound of claim 1 with a specific additional variable w:
Claim 2 repeats the R5 selection language (the same set of phosphate/ester/ether/oligomer motifs) and adds the integer “w” variable as another structural placement or degree parameter in the generic Formula representation.
Scope implication: it keeps the claim broad while restricting which scaffold embodiments are eligible by tying the generic template to a defined parameter value.
What additional structural elements does claim 3 add (A selection, X2, G3/G4, u, a)?
Claim 3 is the other major breadth-defining dependent claim. It changes and augments the scaffold definitions by adding:
1) A linker/atom set “A”
A is selected from:
- absent, optionally substituted alkyl, alkenyl, alkynyl
- —S—, —O—
- —S(O)—, —S(O)2—
- —S[C(R10)(R11)]u— and —S(O)[C(R10)(R11)]u— and —S(O)2[C(R10)(R11)]u—
- —O[C(R10)(R11)]u—
- —N(R10)— and —N(R10)—[C(R10)(R11)]u—
- —[C(R10)(R11)]u—
with u = 1–7.
This is another breadth driver. It permits multiple sulfur/oxygen/nitrogen link types and expands to groups that are structurally dependent on u.
2) Each R1, R2, R3, R4 selection alignment
Claim 3 states that R1/R2/R3/R4 follow the same option sets used in claim 1 for R2/R3/R4.
3) Each G3 and G4 definition
G3 and G4 are selected from:
- —N—
- and —C(R10)[C(R10)(R11)]a—
with a = 0–2.
4) m/q, p, r, and X2
It reintroduces:
- m and q = 0–2
- p = 0–4
- r = 0–11
and adds:
- X2 = —S— or —O—
Scope implication: claim 3 enlarges the definitional flexibility of the core scaffold by allowing alternate linker and ring heteroatom architectures while preserving the same general R5 prodrug-like motifs.
What does claim 4 mean by “R5 selected from Table 1, 2, 3 or 4”?
Claim 4 is a narrowing mechanism. It takes claim 1 and constrains R5 to be selected from predefined embodiments:
- “R5 is selected from Table 1, Table 2, Table 3 or Table 4.”
Claim 4 is significant in claim construction because it:
- converts one broad combinatorial R5 definition into a finite set of enumerated R5 choices
- likely maps to concrete structures enumerated in the specification
Practically, claim 4 supports enforcement against at least those table-listed R5 embodiments while retaining the independent broad coverage of claim 1.
How do claims 5 and 6 differ from claim 4 (specific Formula instances with Table 1)?
- Claim 5: “A compound having the Formula … wherein R5 is selected from Table 1.”
- Claim 6: “A compound having the Formula … wherein R5 is selected from Table 1.”
Even though the provided text omits the actual drawn formulas, the structure suggests claims 5 and 6 are tied to specific base formulas (two different structural templates), each limited to Table 1 selections for R5.
Scope implication: claims 5–6 narrow both the scaffold template and the R5 option set, likely aligning to the most commercially relevant or experimentally validated embodiments.
What does claim 7 cover: “selected compound from Tables A–E” (numbered structures)?
Claim 7 is a selection claim:
- “A compound selected from Table A, B, C, D or E … and geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof.”
The claim includes large numeric tables of “No / Structure” entries:
- Table A: numbered structures 1–121 (as shown)
- Table B: 150–267
- Table C: 300–357
- Table D: 400–437
- Table E: 501–539
Scope implication: claim 7 functionally covers at least those listed compounds individually, including all stereochemical and salt/solvate forms. This is the enforcement backbone for specific embodiments even if Markush interpretation narrows under claim construction.
How many distinct claim layers exist in US 8,431,576 (breadth ladder)?
From the provided claims, the landscape is a ladder:
- Claim 1 (broad Markush core + broad substituents + broad R5 options)
- Claim 2 (adds structural parameter w = 0–11)
- Claim 3 (adds additional scaffold architecture through A, u, G3/G4, X2, etc.)
- Claim 4 (narrows R5 to Tables 1–4)
- Claims 5–6 (narrow both scaffold template and R5 to Table 1)
- Claim 7 (narrows to enumerated structures across Tables A–E)
The presence of both “broad Markush” and “specific structure tables” is typical of patents where the specification enumerates multiple candidate analogs but the independent claim is drafted to cover many not explicitly singled out.
Claim-coverage map: what chemical feature categories are protected
Based strictly on the claim language, the protected feature categories include:
1) Scaffold-level: fused/heteroatom core variability
- Optional absent groups and heteroatom replacements (D includes O, NR10, C(O), S, S(O), S(O)2)
- Integer ring/degree variables (m, q, p, r, t, s)
- R6 allowing cyclization into a second ring
2) Substituent-level: functional groups and heterocycles
- OR10, SR10, N(R10)(R11)
- sulfoxide and sulfone: S(O)R10 and S(O)2R10
- optionally substituted aryl and heterocycle substituents
3) “R5 tail” chemistry: prodrug/ionization enabling motifs
- ether and ester patterns
- amide/carbamoyl-like patterns (OC(O)NR20R21)
- phosphate motifs (OPO3MY; OP(O)(OR20)(OR21); and polymetal-type cation allowances)
This tail chemistry is where many “analog entry” designs attempt to route around patent claims by changing ester vs phosphate vs alkyl prodrugs. Here, the claim spans multiple tail modalities.
Patent landscape implications: how US 8,431,576 would be read in generic/prodrug design-around
1) The claim is broad enough to capture many analogs unless the design avoids the R5 scaffold class
Because claim 1 defines R5 with multiple classes including phosphate and ester-like motifs, a generic developer seeking to avoid infringement would typically need to:
- change the tail chemistry outside all enumerated R5 families, or
- use a different core scaffold such that the generic Formula is not met, or
- remove the allowed linkage patterns that define “R5 selected from …” in claim 1.
The tables in claims 4–7 also create fallback coverage: even if an analog only matches a table-listed R5 pattern, it can still fall into narrower dependents.
2) Salts and solvates are explicitly covered
Even if the active base free acid/base is not the marketed form, the claim includes pharmaceutically acceptable salts and solvates, reducing typical “formulation-only” design-around opportunities.
3) Stereochemical variations are explicitly covered
Geometric isomers, enantiomers, and diastereomers and racemates are included. This makes enantiomer switching a weaker fallback, unless the alternative is designed not to meet the formula parameters.
What litigation and Orange Book status findings can be derived from the claim text alone?
None. The claim text does not supply:
- the drug name (active ingredient) associated with US 8,431,576
- the reference product in FDA Orange Book
- any patent-to-NDA/BLA listing data
- any Paragraph IV, ANDA litigation, settlement date, or FDA exclusivity interactions.
Accordingly, no defensible Orange Book or litigation timeline can be produced from the provided information.
How strong is the patent estate for enforcement based on claim breadth structure?
Based on the claim structure alone:
- Strength factor: claim 1 has expansive Markush coverage across scaffold heteroatom variations and broad R5 prodrug-like motifs.
- Enforcement factor: claim 7 lists many specific embodiments (Tables A–E with large numbering ranges), which helps the patentee anchor infringement allegations to concrete chemical species.
- Potential weakness factor: very broad Markush claims can face enablement or written description challenges depending on how the specification supports each branch. However, no specification text is provided, so no ruling-quality assessment can be made here.
The claim set as provided indicates a design philosophy of “wide independent + enumerated dependent/specific species,” a pattern that often improves enforceability by providing multiple infringement theories across overlapping claim layers.
Key Takeaways
- US 8,431,576 is a broad Markush compound patent covering a general scaffold with extensive substituent and structural parameter latitude (Claims 1–3).
- R5 is the main chemical scope driver and it includes multiple ester/ether and phosphate-like motifs with defined oligomer length (z) and broad R20/R21 and cation allowances.
- Claims 4–6 narrow to specification tables, with R5 restricted to Table 1–4 (and specific scaffold templates for claims 5–6).
- Claim 7 provides concrete coverage by listing many numbered structures across Tables A–E (1–121, 150–267, 300–357, 400–437, 501–539) and includes stereoisomers plus salts/solvates.
- Design-around risk is high for analogs that share the same scaffold and R5 chemistry; sales-form changes (salt/solvate) and stereochemical changes do not inherently avoid infringement due to explicit inclusion.
FAQs
1) Do claims 1 and 7 cover salts and solvates
Yes. Both explicitly include “pharmaceutically acceptable salts and solvates thereof.”
2) Can a competitor avoid infringement by switching enantiomers
Not if the alternative enantiomer still falls within the claimed generic Formula and variable definitions, because claim 1 and claim 7 include enantiomers and diastereomers.
3) Is R5 limited to one prodrug chemistry
No. Claim 1’s R5 includes multiple classes: ethers/esters, amino-carbonyl derivatives, and phosphate/phosphoryl patterns with cation definitions.
4) What does “R5 selected from Table 1” practically do
It narrows R5 to enumerated R5 embodiments tied to the specification’s Tables, limiting which R5 structures are covered under that dependent claim.
5) Does claim 3 expand scaffold architecture beyond claim 1
Yes. Claim 3 adds additional scaffold element options through A (including O, S, N linkages and sulfur/oxygen oxidized variants), u, G3/G4 structures, and X2.
References
No sources were cited because the prompt provided only claim text and did not include the patent document, bibliographic data, specification, prosecution history, or FDA/Orange Book records.
